Published in The Internal Medicine Review, Study Clinically Proves Therapy’s Effectiveness in Reducing & Preventing Nocturnal Muscle Cramps and Spasms

ASHEVILLE, NC (August 24, 2017) Avadim Technologies, Inc. (“Avadim”), the Bionome Therapies™ life sciences company, is pleased to announce today that The Internal Medicine Review, a peer-reviewed publication aimed at providing a sustainable means of communication for academic and professional physicians worldwide, has published an article highlighting the success of Theraworx® Relief as a novel topical therapy for the treatment of nocturnal cramps and spasms and those suffering with moderate to severe Restless legs syndrome. The Internal Medicine Review conducts a thorough double-blind peer review of all submitted research and clinical manuscripts. The editorial board, as well as third party industry professionals, also judges all submissions prior to acceptance for publication. An online version of the article, “Review of Nocturnal Cramps and Introduction of a Novel Topical Therapy,” is currently available to review at

Unlike other topical muscle therapies that provide a superficial heating or cooling sensation, Theraworx® Relief’s unique formulation is made from a proprietary blend of safe ingredients that work with the body’s own natural functions to relieve and even prevent cramps and spasms. Safe for daily use, it does not interfere with medications or other topical products – and is gentle enough to be used by top hospitals, yet powerful enough to be part of the muscle therapy used by elite athletes.

“We are pleased to have our evidence peer-reviewed and published by the science and medical editorial board of The Internal Medicine Review,” said Doctor Joseph Renzulli, II M.D., FACS, and Chief Medical Officer of Avadim Technologies, “29 million Americans suffer with nocturnal cramps and spasms every night and one of our primary goals is to educate this demographic of sufferers and the physicians and other providers who treat them.”

Over the past twelve months, Avadim Technologies has had three peer-reviewed studies published on its topical therapies, and the research and outcomes have been accepted and presented at five national and international medical symposia. These results are a testament to not only to the company’s science, but also its strategic focus in validating the brand’s therapies in the marketplace. The full compendium of evidence continues to grow, enabling Avadim to accelerate customer conversions. The company hopes to continue publishing its future results associated with the symptoms of Restless legs syndrome, as well as the success of its full line of therapies, including Theraworx® Protect, which is used in hospitals and nursing homes across the nation.

To learn more about, please visit or check out Theraworx® Relief on Facebook at

About Avadim Technologies Inc.:

Based in Asheville, North Carolina, Avadim is the Bionome Therapies™ life sciences company. Avadim, has created a new health order by eradicating the existing “sick care” approach to deliver true “health care” through topical Bionome Therapies™ engineered to restore the skin’s natural ecosystem – each with the potential to dramatically enhance the quality of life for a lifetime. People are accepting of today’s standard of care (get sick, treat & repeat) even though it’s inadequate and few companies have stepped up to challenge this simply unacceptable approach that has been in existence for decades. Avadim is the industry leader in delivering true microbiome compliance with effective outcomes. Microbiome compliance ensures the therapy does not negatively effect the colonization of the skin’s microorganisms that human beings depend on to stay alive.

Avadim Technologies Inc. Contacts:
David Fann, President
828.251.7111 Office
904.251.4910 Cell
[email protected]

Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
[email protected]

Avadim Technologies Inc.
81 Thompson Street
Asheville, NC 28803

Investor Relations:
KCSA Strategic Communications
Valter Pinto

Media Contact:
Liz White
Kel & Partners
[email protected]
O: 617.904.9393, ext. 151
C: 978.621.9281